Preclinical News and Research

RSS

New type of stem cell with regenerative abilities could soon become a reality

A new type of stem cell - that is, a cell with regenerative abilities - could be closer on the horizon, a new study led by UNSW Sydney shows.

15 Jan 2021

New model can help identify potential drug targets for ulcerative colitis

Scientists from the Lerner Research Institute at Cleveland Clinic have designed an innovative, patient-derived model of ulcerative colitis that will help scale up studies into new therapies for chronic inflammatory bowel disease.

12 Jan 2021

Main bioactive compound of ginger root counteracts autoimmune diseases in mice

Naturopathic medicine, or herbal medicine, is all the rage, especially among young people. But how much of this is supported by science?

7 Jan 2021

Researchers identify a vital protein needed to regulate anti-tumor immune response

Scientists from The University of Texas MD Anderson Cancer Center have identified a protein known as NF-kappa B-inducing kinase (NIK).

5 Jan 2021

New study reveals a troubling aspect of microplastics

As the plastic in our oceans breaks up into smaller and smaller bits without breaking down chemically, the resulting microplastics are becoming a serious ecological problem.

24 Dec 2020

Scientists discover new class of compounds for combating antimicrobial resistance

Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR). These finding were published today in Nature.

24 Dec 2020

Study: DOT1L enzyme is essential for humoral immune responses

Communication, serendipity and an enzyme called DOT1L have all combined to produce some exciting findings into the immune system's B cells and T cells by two groups of Monash Biomedicine Discovery Institute (BDI) scientists.

17 Dec 2020

New combination therapy could be effective in treating aggressive cancers with common mutations

Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.

15 Dec 2020

New analysis technique could pave way for major breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukaemia.

14 Dec 2020

New antibiotic can help treat drug-resistant pathogens

Researchers from Johns Hopkins University and Medicine have designed a potential new antibiotic for a pathogen that is highly resistant to drugs and is often lethal to individuals suffering from lung diseases, including cystic fibrosis.

11 Dec 2020

Study reveals new target to make breast cancer more sensitive to immunotherapy

Although immunotherapy has been effective in treating different kinds of cancer, it is still unsuccessful when it comes to treating breast cancers.

11 Dec 2020

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

Scientists successfully edit SIV virus from genomes of non-human primates

Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV - a virus closely related to HIV, the cause of AIDS - from the genomes of non-human primates.

1 Dec 2020

Novel targeted therapy blocks critical metabolic pathways in cancer cells

Scientists have designed a new targeted therapy, known as POMHEX, which inhibits vital metabolic pathways in tumor cells containing specific genetic defects.

24 Nov 2020

Researcher develops procedures for defining preclinical stages of Alzheimer's disease

Both of Andrew Kiselica's grandfathers developed dementia when he was in graduate school. As Kiselica was going through neuropsychology training in graduate school, he saw his mother's father become unable to walk or speak due to severe dementia.

12 Nov 2020

Genetic signature in localized prostate cancer can predict likelihood of tumor metastases

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.

11 Nov 2020

New method to improve preclinical evaluation of CAR-T cell therapies

Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies.

9 Nov 2020

LipiDiDiet project shows positive effects of nutrient intervention in early Alzheimer’s disease

Trial participants who received a multinutrient formulation over an extended period of time showed a significantly less rapid deterioration in cognitive performance than the patients in a control group, who received only a placebo.

6 Nov 2020

New type of cancer immunotherapy trains the immune system to eliminate tumor cells

A groundbreaking new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumor cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published in Cell in October.

2 Nov 2020

“Nanobiologic” immunotherapy can train the immune system to eliminate tumor cells

Until recently, it was believed that the innate immune system, the body's first line of defense, lacked the ability to remember pathogens like the adaptive immune system.